`Sent:
`To:
`
`CC:
`
`Wed Jun 28 2006 15:37:27 EDT
`
`;cara
`lansde.n/cambridge/biogen@biogenidec;gihnore o'nei!Vcambridgelbiogen@biogenidec.
`
`Subject:
`
`BG-12 Country Selection Infom1ation - Friday Mtg.
`
`To suppott our Friday meeting (10 AM Cambridge, 4 PM Zug) to discuss Country selection for
`the BG-12 Phase III trials, Clinical has kindly assembled the attached document. The file
`contains the following information:
`
`The first tab is a summary showing the countries, # investigators we've worked with or contacted
`for previous studies, and # new potential investigators that our feasibility CRO were able to get
`to respond to the questionnaire. Most importantly, the comments section provides rationale for
`the Clinical recommendation to use the counny (or not).
`The second tab shows the investigators (both new and previously contacted by us) who were
`used in our assessment, in case there is a question.
`
`I would appreciate it if you could take a look prior to the Friday meeting and come prepared with
`questions and hopefully recommendations.
`
`New Product Commercialization
`Biogen Idee
`
`Page 1 of 1
`
`Biogen Exhibit 2105
`Coalition v. Biogen
`IPR2015-01993
`
`